Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

PD-L1 CPS Scoring Accuracy in Small Biopsies and Aspirate Cell Blocks from Patients with Head and Neck Squamous Cell Carcinoma.

Paintal AS, Brockstein BE.

Head Neck Pathol. 2019 Nov 13. doi: 10.1007/s12105-019-01097-z. [Epub ahead of print]

PMID:
31721075
2.

Association of a Proactive Swallowing Rehabilitation Program With Feeding Tube Placement in Patients Treated for Pharyngeal Cancer.

Ajmani GS, Nocon CC, Brockstein BE, Campbell NP, Kelly AB, Allison J, Bhayani MK.

JAMA Otolaryngol Head Neck Surg. 2018 Jun 1;144(6):483-488. doi: 10.1001/jamaoto.2018.0278.

3.

Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.

Shah S, Ward JE, Bao R, Hall CR, Brockstein BE, Luke JJ.

Cancer Immunol Res. 2016 Nov;4(11):903-909. Epub 2016 Sep 16.

4.

Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.

Campbell NP, Hensing TA, Bhayani MK, Shaikh AY, Brockstein BE.

Expert Rev Anticancer Ther. 2016 Aug;16(8):847-58. doi: 10.1080/14737140.2016.1202116. Epub 2016 Jul 11. Review.

PMID:
27400139
5.

A Contemporary Analysis of Surgical Trends in the Treatment of Squamous Cell Carcinoma of the Oropharynx from 1998 to 2012: A Report from the National Cancer Database.

Liederbach E, Lewis CM, Yao K, Brockstein BE, Wang CH, Lutfi W, Bhayani MK.

Ann Surg Oncol. 2015 Dec;22(13):4422-31. doi: 10.1245/s10434-015-4560-x. Epub 2015 Apr 17.

PMID:
25893414
6.

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE.

J Clin Oncol. 2014 Sep 1;32(25):2735-43. doi: 10.1200/JCO.2013.54.6309. Epub 2014 Jul 21.

7.

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.

Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS.

Ann Oncol. 2013 Jan;24(1):257-63. doi: 10.1093/annonc/mds237. Epub 2012 Aug 21.

8.

Topical polyethylene glycol as a novel chemopreventive agent for oral cancer via targeting of epidermal growth factor response.

Wali RK, Kunte DP, De La Cruz M, Tiwari AK, Brasky J, Weber CR, Gibson TP, Patel A, Savkovic SD, Brockstein BE, Roy HK.

PLoS One. 2012;7(6):e38047. doi: 10.1371/journal.pone.0038047. Epub 2012 Jun 4.

9.

Outcomes of computerized physician order entry in an electronic health record after implementation in an outpatient oncology setting.

Harshberger CA, Harper AJ, Carro GW, Spath WE, Hui WC, Lawton JM, Brockstein BE.

J Oncol Pract. 2011 Jul;7(4):233-7. doi: 10.1200/JOP.2011.000261.

10.

Management of recurrent head and neck cancer: recent progress and future directions.

Brockstein BE.

Drugs. 2011 Aug 20;71(12):1551-9. doi: 10.2165/11592540-000000000-00000. Review.

PMID:
21861540
11.

Head and neck cancer in 2010: Maximizing survival and minimizing toxicity.

Brockstein BE, Vokes EE.

Nat Rev Clin Oncol. 2011 Feb;8(2):72-4. doi: 10.1038/nrclinonc.2010.226. Review.

PMID:
21278773
12.

Head and neck cancers.

National Comprehensive Cancer Network, Forastiere AA, Ang KK, Brizel D, Brockstein BE, Burtness BA, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Goepfert H, Hicks WL Jr, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mittal BB, Pfister DG, Pinto HA, Posner MR, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Weber RS, Wolf GT, Worden F.

J Natl Compr Canc Netw. 2008 Aug;6(7):646-95. No abstract available.

PMID:
18691457
13.

Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels.

Salama JK, Stenson KM, Kistner EO, Mittal BB, Argiris A, Witt ME, Rosen F, Brockstein BE, Cohen EE, Haraf DJ, Vokes EE.

Ann Oncol. 2008 Oct;19(10):1787-94. doi: 10.1093/annonc/mdn364. Epub 2008 Jun 6.

14.

Oncogenic osteomalacia as a harbinger of recurrent osteosarcoma.

Lamont EB, Cavaghan MK, Brockstein BE.

Sarcoma. 1999;3(2):95-9. doi: 10.1080/13577149977712.

15.

Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia.

Carneiro BA, Watkin WG, Mehta UK, Brockstein BE.

Cancer Invest. 2006 Jun-Jul;24(4):396-400.

PMID:
16777692
16.

Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Cohen EE, Kane MA, List MA, Brockstein BE, Mehrotra B, Huo D, Mauer AM, Pierce C, Dekker A, Vokes EE.

Clin Cancer Res. 2005 Dec 1;11(23):8418-24.

17.

Head and neck cancers.

Forastiere AA, Ang K, Brizel D, Brockstein BE, Dunphy F, Eisele DW, Goepfert H, Hicks WL Jr, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mittal BB, Pfister DG, Pinto HA, Posner MR, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Wheeler RH 3rd, Wolf GT, Worden F, Yueh B; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 May;3(3):316-91. No abstract available.

PMID:
16002004
18.

Metastatic osteosarcoma: a curable advanced malignancy.

Brockstein BE.

J Clin Oncol. 2004 Dec 15;22(24):5017; author reply 5017-8. No abstract available.

PMID:
15611520
19.

Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.

Argiris A, Stenson KM, Brockstein BE, Mittal BB, Pelzer H, Kies MS, Jayaram P, Portugal L, Wenig BL, Rosen FR, Haraf DJ, Vokes EE.

Head Neck. 2004 May;26(5):447-55.

PMID:
15122662
20.

Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy.

Argiris A, Brockstein BE, Haraf DJ, Stenson KM, Mittal BB, Kies MS, Rosen FR, Jovanovic B, Vokes EE.

Clin Cancer Res. 2004 Mar 15;10(6):1956-62.

21.

Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer.

Haraf DJ, Rosen FR, Stenson K, Argiris A, Mittal BB, Witt ME, Brockstein BE, List MA, Portugal L, Pelzer H, Weichselbaum RR, Vokes EE.

Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5936-43.

22.

Is patient travel distance associated with survival on phase II clinical trials in oncology?

Lamont EB, Hayreh D, Pickett KE, Dignam JJ, List MA, Stenson KM, Haraf DJ, Brockstein BE, Sellergren SA, Vokes EE.

J Natl Cancer Inst. 2003 Sep 17;95(18):1370-5.

PMID:
13130112
23.

Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.

Rosen FR, Haraf DJ, Kies MS, Stenson K, Portugal L, List MA, Brockstein BE, Mittal BB, Rademaker AW, Witt ME, Pelzer H, Weichselbaum RR, Vokes EE.

Clin Cancer Res. 2003 May;9(5):1689-97.

24.

Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.

Masters GA, Brockstein BE, Mani S, Ratain MJ.

Med Oncol. 2003;20(1):7-12.

PMID:
12665678
25.

Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.

Vokes EE, Stenson K, Rosen FR, Kies MS, Rademaker AW, Witt ME, Brockstein BE, List MA, Fung BB, Portugal L, Mittal BB, Pelzer H, Weichselbaum RR, Haraf DJ.

J Clin Oncol. 2003 Jan 15;21(2):320-6.

PMID:
12525525
26.

Reduction of distant metastases in head and neck cancer with concomitant chemotherapy.

Brockstein BE.

J Clin Oncol. 2000 Sep 15;18(18):3320-1. No abstract available.

PMID:
10986067
27.

Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors.

Brockstein BE, Smiley C, Al-Sadir J, Williams SF.

Bone Marrow Transplant. 2000 Apr;25(8):885-94.

28.

Oral chemotherapy in head and neck cancer.

Brockstein BE, Vokes EE.

Drugs. 1999;58 Suppl 3:91-7. Review.

PMID:
10711847
29.

Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.

Vokes EE, Haraf DJ, Brockstein BE, Weichselbaum RR.

Semin Radiat Oncol. 1999 Apr;9(2 Suppl 1):70-6.

PMID:
10210543
30.

Oral 5-FU alternatives for the treatment of head and neck cancer.

Vokes EE, Brockstein BE, Humerickhouse R, Haraf DJ.

Oncology (Williston Park). 1998 Oct;12(10 Suppl 7):35-8. Review.

31.

Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.

Vogelzang NJ, Mani S, Schilsky RL, Ansari RH, Taber D, Rhinehart SN, Garcia JC, Meyer SC, Mick R, Brockstein BE, Stadler WM, Ratain MJ, Vokes EE.

Clin Cancer Res. 1998 Apr;4(4):929-34.

32.
33.

Supplemental Content

Loading ...
Support Center